Cargando…

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies

Background: Treatment of HR-NB comprise induction, consolidation with autologous stem cell transplant (ASCT) followed by anti-GD2 immunotherapy and isotretinoin. Childrens Oncology Group and SIOPEN studies used dinutuximab and cytokines to treat patients in complete remission or refractory Bone/Bone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mora, Jaume, Castañeda, Alicia, Flores, Miguel A., Santa-María, Vicente, Garraus, Moira, Gorostegui, Maite, Simao, Margarida, Perez-Jaume, Sara, Mañe, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723438/ https://www.ncbi.nlm.nih.gov/pubmed/33324208 http://dx.doi.org/10.3389/fphar.2020.575009

Ejemplares similares

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
por: Mora, Jaume, et al.
Publicado: (2023)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
por: Muñoz, Juan Pablo, et al.
Publicado: (2023)

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
por: Varo, Amalia, et al.
Publicado: (2023)

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
por: Mora, Jaume
Publicado: (2022)

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain
por: Castañeda, A., et al.
Publicado: (2022)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
por: Castillo‐Ecija, Helena, et al.
Publicado: (2021)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

LGG-29. Use of Bevacizumab in Pediatric Low-grade Glioma: Ten-year experience in a single center
por: Rafael, Margarida Simão, et al.
Publicado: (2022)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G(D2) immunotherapy and isotretinoin
por: Kushner, Brian H., et al.
Publicado: (2015)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al
por: Mora, Jaume, et al.
Publicado: (2021)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Parathyroid hormone‐like hormone plays a dual role in neuroblastoma depending on PTH1R expression
por: García, Marta, et al.
Publicado: (2019)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
por: Garcia-Gerique, Laura, et al.
Publicado: (2022)

Polymorphisms in the Calcium-Sensing Receptor Gene Are Associated with Clinical Outcome of Neuroblastoma
por: Masvidal, Laia, et al.
Publicado: (2013)

Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022)

Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment
por: Luksch, R, et al.
Publicado: (2005)

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Correction to: Multidisciplinary Clinical Care in the Management of Patients Receiving Anti‑GD2 Immunotherapy for High‑Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2023)

Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid
por: Hettmer, S, et al.
Publicado: (2004)

Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
por: Benitez-Ribas, Daniel, et al.
Publicado: (2018)

Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
por: Benitez-Ribas, Daniel, et al.
Publicado: (2018)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells
por: Acosta, Sandra, et al.
Publicado: (2009)

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma
por: Corrias, M V, et al.
Publicado: (2008)

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
por: Schmitt, Julia, et al.
Publicado: (2022)

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2018)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
por: Tas, Michelle L., et al.
Publicado: (2021)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ereafce207urrq8h506odb5s4d